Legend Biotech (NASDAQ:PLRX) Now Covered by Analysts at Piper Sandler

Piper Sandler started coverage on shares of Legend Biotech (NASDAQ:PLRX) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $50.00 price target on the stock. Piper Sandler also issued estimates for Legend Biotech’s Q2 2020 earnings at ($1.05) EPS, Q3 2020 earnings at ($0.70) EPS, Q4 2020 earnings at ($1.55) EPS, FY2020 earnings at ($3.30) EPS, Q1 2021 earnings at ($0.50) EPS, Q2 2021 earnings at ($0.55) EPS, Q3 2021 earnings at ($0.60) EPS, Q4 2021 earnings at ($0.60) EPS and FY2021 earnings at ($2.25) EPS.

PLRX opened at $29.53 on Monday. Legend Biotech has a fifty-two week low of $21.05 and a fifty-two week high of $35.63.

Legend Biotech Company Profile

Pliant Therapeutics, Inc, a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH.

Recommended Story: How can investors invest in the S&P/TSX Index?

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.